Hanmi Pharmaceutical Co., Ltd.
Hanmi is a No.1 R&D pharmaceutical company in Korea, developing new treatments for diabetes, obesity, cancer, autoimmune and rare disease. One of the focused therapeutic areas is Oncology/Hematology. HM43239 is a novel orally active small molecule inhibitor of fms-like tyrosine kinase (FLT3) that is a potentially effective treatment to patients with hematologic malignancies including acute myeloid leukemia (AML). The Phase 1/2 clinical trial in paitent with refractory/relapsed AML is ongoing in US and Korea. The interim data will be orally presented during the annual meeting.